Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance

M.B., C.C., C.M., and P.S. have received institutional funding from Merck, Ferring, Theramex, Gedeon Richter, and Besins. M.B. has received personal honoraria from Merck, Ferring, Gedeon Richter, Theramex, IBSA, and Organon for lectures, presentations, or educational events, and has received non-monetary support for attending meetings from Ferring and Gedeon Richter. C.C. has received personal honoraria from Merck, Besins, Gedeon Richter, and Theramex, and non-monetary support for attending meetings from Besins, Gedeon Richter, and Merck. He is the Founder and Past-President of the Society for Endometriosis and Uterine Disorders (SEUD), an unpaid role. C.M. has received personal consulting fees from Gedeon Richter and Ferring and honoraria from Merck Serono, Ferring, Besins, IBSA, and Organon for lectures or educational events. She has received non-monetary support for attending meetings from Ferring, Besins, and Gedeon Richter. P.S. has received personal honoraria from Merck, Ferring, Besins, Gedeon Richter, Theramex, IBSA, and General Electrics Medical Systems for lectures and educational events. He has also received non-monetary support for attending meetings from Merck, Ferring, Besins, Gedeon Richter, Theramex, and IBSA. He is a Board Member of SEUD and serves on the Editorial Boards of RBMO and GOF, all unpaid roles. J.G. has received institutional funding from Pregnomic and DiaSorin. He has received personal honoraria from Elsevier and Merck for lectures and educational events. He is a Board Member of ABA and SFE, an unpaid position. L.C., J.-M.T., and A.H. declare no conflicts of interest.

Laurent Chouchana, Pharmacology Department, Regional Center of Pharmacovigilance, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France; «Pharmacologie et évaluation des thérapeutiques chez l’enfant et la femme enceinte», Université Paris Cité, INSERM UMR-S1343, Paris, France. Alexandra Henry, Pharmacology Department, Regional Center of Pharmacovigilance, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France; «Pharmacologie et évaluation des thérapeutiques chez l’enfant et la femme enceinte», Université Paris Cité, INSERM UMR-S1343, Paris, France. Mathilde Bourdon, Faculté de Santé, Université Paris Cité, Paris, France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France; Department 3I « Infection, Immunité et inflammation », Institut Cochin, INSERM U1016, Paris, France. Chloé Maignien, Faculté de Santé, Université Paris Cité, Paris, France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France. Charles Chapron, Faculté de Santé, Université Paris Cité, Paris, France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France; Department 3I « Infection, Immunité et inflammation », Institut Cochin, INSERM U1016, Paris, France. Jean-Marc Treluyer, Pharmacology Department, Regional Center of Pharmacovigilance, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France; «Pharmacologie et évaluation des thérapeutiques chez l’enfant et la femme enceinte», Université Paris Cité, INSERM UMR-S1343, Paris, France. Jean Guibourdenche, Faculté de Santé, Université Paris Cité, Paris, France; Department of Hormonology, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France. Pietro Santulli, Faculté de Santé, Université Paris Cité, Paris, France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Cochin Hospital, AP-HP.Centre—Université Paris Cité, Paris, France; Department 3I « Infection, Immunité et inflammation », Institut Cochin, INSERM U1016, Paris, France.